Evidence-Based Complementary and Alternative Medicine
Volume 2018 (2018), Article ID 8514619, 12 pages
https://doi.org/10.1155/2018/8514619

Research Article

UHPLC-Q-TOF MS-Based Metabolic Analysis for the Therapeutic Efficacy of “Xuebijing Injection” against Sepsis-Induced Acute Lung Injury

Xuan Shi, Guannan Chen, Juan Wei, Di Feng, Yuanli Chen, Huanping Zhou, Meiyun Liu, and Xin Lv

Department of Anesthesiology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China

Correspondence should be addressed to Xin Lv; xinlvg@126.com

Received 23 May 2018; Revised 1 July 2018; Accepted 6 August 2018; Published 23 September 2018

Academic Editor: Pierre Champy

Copyright © 2018 Xuan Shi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

“Xuebijing Injection” (XBJ) is a traditional Chinese medicine and has been wildly used in the treatment of sepsis in China. However, few studies have reported the use of XBJ in sepsis with acute lung injury (ALI). This study aimed to investigate the therapeutic efficacy of XBJ against sepsis-induced ALI. Generally a total of 27 mice were equally randomized into three groups: a sham group was given saline before sham operation. A sepsis group received the cecal ligation and puncture (CLP) operation only. A sepsis+XBJ group, XBJ, was injected at 72, 48, and 24 h before CLP operation. The lung tissue was collected for UHPLC-Q-TOF/MS profiling analysis, biomarker identification, and pathway analysis. With the analysis of principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA), forty-five purine, amino acid, and sphingolipid metabolites in lung tissues were identified as potential biomarkers of sepsis-induced ALI, among which 22 were reversed in the sepsis+XBJ group significantly. Conclusively, our results suggest that purine metabolic pathway, glutathione metabolic pathway, sphingomyelin metabolic pathway, arachidonic acid metabolic pathway, and phospholipid metabolic pathway may be the potential therapeutic pathways to overcome sepsis-induced acute lung injury and we provided the potential mechanisms of protective effects of XBJ against ALI.

1. Introduction

Sepsis, characterized by high morbidity and mortality rate, has been the leading cause of critical illness worldwide [1, 2]. Among these patients, over 40% are at risk of progressing to acute lung injury (ALI), a lung disease with high morbidity [3, 4]. The treatments for sepsis-induced ALI include liquid resuscitation, antibiotic therapy, blood purification, and stem cell therapy. Despite the tremendous progress in the understanding of the mechanism of sepsis in the field of intensive medicine and other basic sciences, the mortality rate remains at a high level over the past few decades, especially in low- and middle-income countries [5]. Xuebijing injection (XBJ), a traditional Chinese herbal prescription, has been approved by the State Food and Drug Administration (SFDA) and widely used in the clinical treatment of severe sepsis. XBJ is made up of more than 20 constituents including chlorogenic acid, hydroxysafflor yellow A, rutin, and ferulic acid [6, 7]. It is an anti-inflammatory drug and has been widely used in China to block the progression of sepsis and reduce the incidence and mortality of sepsis [8]. In addition, XBJ can shorten the mean length of hospitalization, the Acute Physiology and Chronic Health Evaluation-II score (APACHEII score), White Blood Cell (WBC), C-Reactive Protein (CRP), Neutrophil (NEU), and Temperature (T⁰) of patients with sepsis. Above all, XBJ treatment can reduce the 28-day mortality of patients with severe sepsis [9]. However, the mechanisms of “Xuebijing injection” against sepsis-induced acute lung injury has is still not clear, and comprehensive mechanisms remain to be elucidated.

Metabolomics is a rapidly advancing field after the development of genomics, transcriptomics, and proteomics and can serve as a tool for the analysis of biological tissues [10]. Metabolomics can show us a better perspective to explore the entire organisms [11]. This technology can be also used to assess the holistic efficacy of traditional Chinese medicines and reveal the biomarkers of sepsis and sepsis-induced acute lung injury [12, 13]. In this study, it is the first time to use a metabonomic-based approach to explore the comprehensive changes in lung tissues in a murine model of sepsis-induced ALI and the therapeutic efficacy of XBJ against ALI.

2. Materials and Methods

2.1. Reagents

XBJ was purchased from CHASE SUN Co., Ltd (Tianjin, China). Formic acid (FA) (HPLC grade) was purchased from the Fluka Chemical Corp (Buchs, Switzerland). Methanol (HPLC grade) and acetonitrile (HPLC grade) were purchased from Merck (Darmstadt, Germany). 2-Chloro-L-phenylalanine (Sigma-Aldrich, St Louis, MO, USA) was used as an internal standard. Chromatography mass spectrometry (GC-MS) was performed using the Milli-Q system (Millipore, Bedford, MA, USA) with ultrapure water.

2.2. Animals and Groups

Male specific-pathogen-free C57B/L6 mice weighing 21-25g (Animal Lab Center of the Navel Medical University, Shanghai, China) were housed in a standard 12h light/dark cycle, constant temperature condition with free access to food and water. All the experiments were approved by the Animal Care and Use Committee of Tongji University (Shanghai, China). Sepsis was induced by cecal ligation and puncture (CLP) as described before [14]. Twenty-seven equally randomized into 3 groups: sham group, treated with sham operation, and saline only; model group; and treatment group, treated with 4ml/kg XBJ injection (CHASE SUN Co., Ltd. Tianjin, China) via the tail vein at 72, 48, and 24 h before CLP [15]. The lung tissues were collected from each group and stored at -80°C for future study.

2.3. Histology and Immunohistochemistry Analysis

After the experiments were finished, the lung tissues were perfused with normal saline (NS), inflated with 1ml formalin and removed en bloc after tracheal ligation. After that, the lung tissues were fixed in 10% PBS buffered formalin for 24 h at room temperature and embedded in paraffin. Hematoxylin and eosin (H&E) staining was performed using the standard protocol. For immunohistochemistry of ICAM and VCAM, tissue sections or cells were incubated with the primary rabbit anti-ICAM (1:2000; cell signal tech, Boston, USA) and anti-VCAM (1:2000; cell signal tech, Boston, USA) antibody, followed by the secondary goat anti-rabbit antibody (Beyotime Institute of Biotechnology, Shanghai, China). Immunohistochemical images were captured with a digital camera (Nikon, Tokyo, Japan).

2.4. Sample Preparation and Test

The frozen lung tissues were thawed at room temperature, added with 0.3ml ice-cold methanol containing 25μg/ml 2-chloro-L-phenylalanine as the internal standard to precipitate the protein and extract the metabolites, and mixed by vortex 5 min. These samples were tranquilized for 10 min. After centrifugation at 13000rpm, 4°C for 15 min, the clear supernatant was transferred to a sampler vial.

A quality control (QC) sample was used to monitor the data acquisition performance during analysis. The QC sample was prepared by pooling aliquots from all lung samples collected in our study.

2.5. UHPLC-Q-TOF MS Analysis

UHPLC-Q-TOF/MS profiling analysis was performed using an Agilent 1290 Infinity LC system equipped with an Agilent 6530 Accurate-Mass Quadrupole Time-of-Flight (Q-TOF) mass spectrometer (Agilent Technologies, USA). Chromatographic separations were performed at 40°C using an Acquity UPLC HSS T3 column (2.1 mm × 100 mm, 1.8 μm; Waters, Milford, MA, USA). The mobile phase was composed of 0.1% formic acid (A) and ACN modified with 0.1% formic acid (B). The total run time for one sample was 25 min including 6 min for equilibration and the optimized UHPLC elution conditions were set at: 5%B, 0-2 min; 5%-15%B, 2-10 min; 15%-30%B, 10-14 min; 30%-95%B, 14-17 min; and 95%B, 17-19 min. The injection volume was 3 μL and the flow rate was set to 0.4 ml/min, and the autosampler was maintained at 4°C.

An electrospray ionization source (ESI) was operated in both positive and negative ion modes of operation. The optimized conditions used were as follows: capillary voltage, 4 kV for the positive mode and 3.5 kV for the negative mode; drying gas flow, 11 L/min; gas temperature, 350°C; fragment or voltage, 120 V; nebulizer pressure, 45 psig; and skimmer voltage, 60 V. Data were collected in the profile mode and the mass range was set from 50 to 1,100 m/z. The biomarkers were further analyzed by MS/MS, and the collision energy was set from 10 to 40 eV.

2.6. Statistical Analysis

The UHPLC-MS raw data in the instrument specific format were converted to common (mz.data) data format files using the Agilent Mass Hunter Qualitative software (Agilent Technologies, USA), in which the threshold was set to 0.1% and all isotope interferences were excluded. The XCMS program [16] (https://xcmsonline.scripps.edu) was used for peak extraction, retention time correction, RT alignment, and integration, in order to generate a visualization matrix. The ions were filtered to an 80% concentration [17], and to correct the MS response shift, all detected ions in each sample were normalized to total intensity. The three-dimensional (3D) data, including the sample names, RT, and m/z pairs, were imported to SIMCA-P software (version 11.0, Umetrics, Umea, Sweden) for principal component analysis (PCA) and partial least squares discriminate analysis (PLS -DA). Variable importance plot (VIP) with the threshold value of 1 was used to select metabolites. Data are represented as mean ± standard deviation (SD). The statistical significant differences were analyzed by SPSS 17.0, using Student’s t-test and one-way ANOVA. P < 0.05 was considered statistically significant.

2.7. Identification of Biomarkers and Pathway Analysis

To identify the discovered biomarkers, the exact masses of ion were input into databases such as Metlin (http://metlin.scripps.edu), Human Metabolome Database (http://www.hmdb.ca/) and PubChem (http://pubchem.ncbi.nlm.nih.gov). The metabolic pathway was drawn by the Smartdraw software (SmartDraw 7.5 Hemera Technologies Inc) based on the biomarkers found in the experiment.

3. Results

3.1. Histopathology

To assess the protective effect of XBJ, the lung tissue sections were observed under a light microscope. As shown in Figure 1, after CLP, the lung tissues in the model group displayed thick lung septa, vascular congestion, and expansion and became congested by neutrophils. However, the severity was ameliorated after XBJ treatment as compared with the model group.

Figure 1: XBJ ameliorates the acute lung injury induced by septic. Upper panel: hematoxylin and eosin staining of lung tissues. Magnification, ×200. Middle panel: immunohistochemical staining of ICAM in lung tissues. Magnification, ×200. Lower panel: immunohistochemical staining of VCAM in lung tissues. Magnification, ×200.

ICAM and VCAM are two types of proinflammatory adhesion molecules. As shown Figure 1, the expression of ICAM and VCAM in the treatment group was significantly decreased as compared with the model group.

3.2. Metabolic Profiling Analysis of Lung Tissues

UHPLC-Q-TOF/MS data of the lung tissues were acquired based on the above methods. Figure 2 shows the representative total ion chromatograms (TICs) in the positive mode and negative mode. These two figures displayed the general information of UHPLC-Q-TOF/MS detection. PCA score plot showed that the QC samples gathered into groups tightly, indicating that this system was stable. As shown in Figure 3, together with PLS-DA scatter plot and variable importance plots (VIPs), we defined different metabolites in the three groups. The metabolites that we chose were the points far away from the origin point in Figures 3(a) and 3(b). The metabolites with VIPs > 1.0 were considered to be important differential biomarkers. Then in Figures 3(c) and 3(d), the positive and negative modes of supervised partial least squares discriminate analysis (PLS-DA) plot were used to screen potential metabolite biomarkers from the obtained data [18]. One-way ANOVA and Tukey’s post hoc test were used to assess the statistical significance.

(a)

(b)

Figure 2: The representative TICs in the positive and negative mode. Representative total ion current (TIC) chromatograms of lung tissues obtained from different group of rats in the (a) positive mode and (b) negative mode. Upper panel: sham group; middle panel: model group; lower panel: treatment group.

(a)

(b)

(c)

(d)

Figure 3: PLS-DA and VIP-score plot in the positive and negative modes. The combination of S- and VIP-score plot in the (a) positive and (b) negative modes showed that a greater number of values obtained from the lung tissues were further away from the origin. Score plots of the principal component analysis performed on the HPLC/MS profile of rat lung tissues obtained from the sham group (black squares), model group (red rounds), and treatment group (blue rhombus) in the (c) positive mode and (d) negative mode.

3.3. Identification of Biomarkers

To identify biomarkers, we used the extracted ion chromatogram (EIC) to confirm the ions and then put the accurate molecular mass of ions into the Mass Bank (http://www.massbank.jp/), Metlin (http://metlin.scripps.edu/) and Human Metabolome Database (http://www.hmdb.ca/) to verify the structure that we speculated [17, 19]. Then, detected the corresponding quasi-molecular ion peak according to the retention time (RT) in the extracted ion chromatogram (EIC) of m/z 137.0458 (Figure 4(b)). Measured by Agilent MassHunter software, the accurate mass was 137.0458, and C₅H₄N₄O was calculated as the most probable molecular formula. Then, the m/z of 137.0458 was identified as hypoxanthine by considering the elemental composition, fragmentation pattern, and chromatographic retention behavior, which was validated by a standard compound (Figure 4(c)). Similarly, other biomarkers have been identified according to the above method and are listed in Table 1 [20].

Table 1: Identification of significantly differential metabolites for lungs from control, CLP, and XBJ treated groups by UPLC-MS/TOF. Identification of significantly differential metabolites for lung from control, CLP, and XBJ injection treated groups by UPLC-MS/TOF. Potential biomarkers related to endotoxemia induced acute lung injury and the related metabolic pathways. Metabolites validated with standard sample. Metabolites putatively annotated.

NO
RT/min
Detected M/Z
Theoretical M/Z
Ion
Formula
PPM
Metabolites
Fold change
Related pathway

LPS/CON
LPS+XBJ/LPS

1
0.70
132.0766
132.0768
[M+H]⁺
C₄H₉N₃O₂
1.51
Creatine
0.48
1.55
Glycine, serine and threonine metabolism

2
1.01
137.0458
137.0458
[M+H]⁺
C₅H₄N₄O
0
Hypoxanthine
0.39
1.19
Purine metabolism

3
1.05
151.0254
151.0261
[M-H]⁻
C₅H₄N₄O₂
4.63
Xanthine
0.78
1.11
Purine metabolism

4
1.01
169.0358
169.0356
[M+H]⁺
C₅H₄N₄O₃
1.18
Uric acid
1.76
0.80
Purine metabolism

5
1.01
308.0907
308.0911
[M+H]⁺

1.30
Glutathione
0.32
2.57
Glutathione metabolism

6
1.01
306.0742
306.0765
[M-H]⁻

7.51
Glutathione
0.29
2.00
Glutathione metabolism

7
1.31
132.1018
132.1019
[M+H]⁺
C₆NO₂
0.76
L-Leucine
0.98
1.02
Valine, leucine and isoleucine metabolism

8
8.45
274.2743
274.2741
[M+H]⁺
NO₂
0.73
C16 Sphinganine
0.66
2.86
Sphingolipid metabolism

9
9.80
300.2902
300.2897
[M+H]⁺
NO₂
1.67
Sphingosine
0.93
0.56
Sphingolipid metabolism

10
10.84
339.2895
339.2894
[M+H]⁺
O₃
0.29
Glycidyl oleate
1.39
1.43
Linoleic acid metabolism

11
14.17
255.2320
255.2330
[M-H]⁻
O₂
3.92
Palmitic acid
0.80
0.79
Fatty acid metabolism

12
13.44
303.2319
303.2330
[M-H]⁻
O₂
3.63
Arachidonic Acid
0.72
1.44
Arachidonic acid metabolism

13
10.11
478.2934
478.2928
[M+H]⁺
NO₇P
1.25
LysoPE(18:2/0:0)
1.85
1.21
Phospholipid metabolism

14
10.18
526.2935
526.2928
[M+H]⁺
NO₇P
1.33
PE(22:6/0:0)
1.28
1.34
Phospholipid metabolism

15
10.18
502.2933
502.2928
[M+H]⁺
NO₇P
1.00
LysoPE(20:4/0:0)
1.41
1.25
Phospholipid metabolism

16
10.18
361.2741
361.2737
[M+H]⁺
O₃
1.11
O-Arachidonoyl Glycidol
1.44
1.23
Phospholipid metabolism

17
10.21
568.3400
568.3398
[M+H]⁺
NO₇P
0.35
LysoPC(22:6)
0.59
1.37
Phospholipid metabolism

18
10.21
544.3405
544.3398
[M+H]⁺
NO₇P
1.29
LysoPC(20:4)
0.76
1.08
Phospholipid metabolism

19
10.24
520.3404
520.3398
[M+H]⁺
NO₇P
1.15
LysoPC(18:2)
0.84
0.81
Phospholipid metabolism

20
10.44
528.3090
528.3085
[M+H]⁺
NO₇P
0.95
LysoPE(22:5/0:0)
1.29
1.59
Phospholipid metabolism

21
10.57
504.3087
504.3085
[M+H]⁺
NO₇P
0.40
LysoPE(20:3/0:0)
1.35
1.46
Phospholipid metabolism

22
10.62
496.3404
496.3398
[M+H]⁺
NO₇P
1.21
LysoPC(16:0)
0.61
2.31
Phospholipid metabolism

23
10.69
454.2933
454.2928
[M+H]⁺
NO₇P
1.10
LysoPE(0:0/16:0)
0.94
0.84
Phospholipid metabolism

24
10.84
480.3093
480.3085
[M+H]⁺
NO₇P
1.67
LysoPE(18:1/0:0)
1.47
1.44
Phospholipid metabolism

25
11.01
482.3610
482.3605
[M+H]⁺
NO₆P
1.04
PC(O-16:0/0:0)
1.63
0.79
Phospholipid metabolism

26
11.03
530.3247
530.3241
[M+H]⁺
NO₇P
1.13
LysoPE(22:4/0:0)
1.70
1.38
Phospholipid metabolism

27
11.09
438.2985
438.2979
[M+H]⁺
NO₆P
1.37
PE(P-16:0/0:0)
1.01
0.67
Phospholipid metabolism

28
11.16
506.3244
506.3241
[M+H]⁺
NO₇P
0.59
LysoPE(20:2/0:0)
1.54
1.43
Phospholipid metabolism

29
11.99
524.3717
524.3711
[M+H]⁺
NO₇P
1.14
PC(18:0/0:0)
1.06
0.97
Phospholipid metabolism

31
12.01
558.3555
558.3530
[M+H]⁺
NO₇P
4.48
PC(21:4/0:0)
1.58
1.48
Phospholipid metabolism

32
12.01
482.3248
482.3241
[M+H]⁺
NO₇P
1.45
LysoPE(0:0/18:0)
0.81
0.79
Phospholipid metabolism

33
12.03
508.3400
508.3398
[M+H]⁺
NO₇P
0.39
LysoPE(20:1/0:0)
1.41
1.52
Phospholipid metabolism

34
12.35
510.3918
510.3918
[M+H]⁺
NO₆P
0
PC(O-18:0/0:0)
2.18
0.66
Phospholipid metabolism

36
10.63
452.2777
452.2783
[M-H]⁻
NO₇P
1.33
PE(16:0/0:0)
0.81
0.50
Phospholipid metabolism

37
10.14
476.2777
476.2783
[M-H]⁻
NO₇P
1.26
LysoPE(0:0/18:2)
1.45
0.95
Phospholipid metabolism

38
10.87
478.2936
478.2939
[M-H]⁻
NO₇P
0.63
PE(18:1/0:0)
1.24
0.98
Phospholipid metabolism

39
12.09
480.3088
480.3096
[M-H]⁻
NO₇P
1.67
LysoPE(0:0/18:0)
0.91
0.83
Phospholipid metabolism

40
10.21
500.2779
500.2783
[M-H]⁻
NO₇P
0.80
LysoPE(0:0/20:4)
1.23
0.96
Phospholipid metabolism

41
10.59
502.2930
502.2939
[M-H]⁻
NO₇P
1.79
LysoPE(0:0/20:3)
1.15
0.99
Phospholipid metabolism

42
10.20
524.2782
524.2783
[M-H]⁻
NO₇P
0.19
LysoPE(0:0/22:6)
1.12
1.04
Phospholipid metabolism

43
10.78
526.2934
526.2939
[M-H]⁻
NO₇P
0.95
LysoPE(0:0/22:5)
1.33
1.02
Phospholipid metabolism

44
11.07
528.3093
528.3096
[M-H]⁻
NO₇P
0.57
LysoPE(0:0/22:4)
1.37
0.96
Phospholipid metabolism

45
10.64
540.3303
540.3307
[M+FA-H]⁻
NO₇P
0.74
PC(16:0/0:0)
0.87
0.91
Phospholipid metabolism

46
10.99
566.3454
566.3463
[M+FA-H]⁻
NO₇P
1.59
PC(P-16:0/2:0)
0.66
1.06
Phospholipid metabolism

47
12.04
568.3616
568.3620
[M+FA-H]⁻
NO₇P
0.70
PC(O-16:0/2:0)
1.05
0.92
Phospholipid metabolism

48
10.23
588.3298
588.3307
[M+FA-H]⁻
NO₇P
1.53
PC(20:4/0:0)
0.68
0.99
Phospholipid metabolism

(a)

(b)

(c)

(d)

Figure 4: Identification of a selected marker (m/z=137.0458). (a) Extracted ion chromatogram (EIC) of a commercial standard hypoxanthine (=0.996 min); (b) EIC of m/z 137.05 (=0.997min); (c) MS/MS spectrum of a commercial standard hypoxanthine; (d) MS/MS spectrum of the ion. The collision energy was 10V.

3.4. Evaluation of the Mechanism Underlying the Effect of XBJ on Sepsis-Induced ALI

Finally, we identified 45 metabolites in the lung tissues to be the potential biomarkers of sepsis-induced ALI. These metabolites were valid to evaluate the protective effect of XBJ on sepsis-induced ALI. According to these statistics, we established a PCA model, R2X=0.544 and Q2=0.56, demonstrating that the model was reliable and predictive. All identified different metabolites are listed in Table 1, indicating that, among these 45 metabolites identified, 22 metabolites were reversed in the treatment group. Furthermore, the heatmap of these 45 metabolites was presented in Figure 5 both in positive and negative mode. To gain an insight into metabolic changes in different groups, we put the data into Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (http://www.genome.jp/kegg/). The pathways of the identified metabolites are shown in Figure 6 by mainly focusing on fatty acid metabolism, amino acid metabolism, purine metabolism, and phospholipid metabolism.

(a)

(b)

Figure 5: The heatmap showed the expression levels of differential metabolites. Heatmap visualization of the differential metabolites in these three groups in positive (a) and negative ion mode (b). In this picture, each row represents a metabolite and each column represents the expression level (red: upregulation; blue: downregulation).

Figure 6: A metabolic pathway map showed the changed metabolites and their related pathway in model group or after XBJ treatment. The metabolic pathway networks related to the different metabolites between sepsis-induced acute lung injury and XBJ treatment groups. Red biomarkers in the networks are upregulated and the green ones are downregulated.

4. Discussion

Sepsis is a common clinical condition associated with septic shock and MODS in ICUs. More than 40% patients with sepsis are at risk of progressing to ALI [4]. Previous studies showed that Gram-negative bacterial infections still play a central role in the pathogenesis of ALI and ARDS [21]. In this study, we established the sepsis-induced ALI model following the method described previously [14]. It was found in our study that the metabolites promoting oxidative stress were reduced significantly and after XBJ treatment the symptoms of ALI were alleviated, and the survival rate was improved.

No effective methods are currently available for the clinical treatment of sepsis-induced ALI. The meta-analysis performed by Shi H el al. showed that XBJ had a significant clinical effect on patients with sepsis [9]. But the extract efficacy of XBJ remains unclear. Inflammatory mediators, such as ICAM and VCAM, block the microvessels and lead to activation of leukocytes to release inflammatory mediators. These mediators can also release a large amount of oxygen free radicals [22, 23]. What is more, ICAM and VCAM are the mediators after the stimulation of TNF-α, IL-1, and endotoxin, leading to adhesion, aggregation, rolling, and exudation of leukocytes [24].

It was found in this study that less ICAM and VCAM gathered in the XBJ treatment as compared with the model group, indicating that XBJ was able to ameliorate sepsis-induced ALI via reducing the production of ICAM and VCAM.

Based on the results obtained from the lung tissues and comparison with the information from the databases such as HMDB, we finally identified a series of biomarkers and related pathways in the treatment group versus the model group. These pathways involved purine, glutathione, sphingomyelin, arachidonic acid metabolisms, and phospholipid metabolism.

Compared with the sham group, we observed that xanthine and hypoxanthine were downregulated, and uric acid was upregulated, and XBJ treatment could reverse these conditions.

Annette et al. [23] found that, in the process of oxidative stress, the amount of xanthine oxidase would be enhanced significantly. The xanthine oxidase (XO) could break down hypoxanthine and xanthine to uric acid and release superoxide, which is consistent with our experimental result. Previous studies [25] reported that the level of uric acid in patients with infection was elevated significantly and associated with poor prognosis. In our study, XBJ alleviated oxidative stress in lung tissues after CLP. What is more, XBJ suppressed the activation of xanthine oxidase, thus increasing the level of xanthine and hypoxanthine and decreasing the level of uric acid. These results imply that XBJ could favorably affect sepsis-induced ALI via the purine metabolic pathway.

Mervyn et al. and Novelli et al. [26–28] demonstrated that antioxidant depletion such as glutathione (GSH) was one of the most important characteristics in septic patients, which may ultimately lead to severe oxidative stress. Upregulation and activation of GSH could final ameliorate inflammation and histological injury of lung tissues [29]. In our study, we also observed the same phenomenon that the quantity of GSH was declined significantly, but the quantity of GSH was enhanced after XBJ treatment, indicating that XBJ may be a therapeutic option for sepsis-induced ALI through alleviating oxidative stress.

Sphingosine is a kind of bioactive lipid present in cell membranes. Previous studies [30] found that sphingosine exerted a critical role in signal transduction and participated in the process of growth, senescence, differentiation, and apoptosis. Published articles [26, 27, 29] showed that sphingolipid metabolism also played a critical role in oxidative stress. When sepsis occurs, it is in oxidative status, which causes severe cell membrane damage and sphingolipid loss. As a result, the body needs large amounts of sphingosine to compensate for the sphingolipid loss. It was found in our study that the amount of sphingosine in the model group was reduced significantly as compared with the control group, and XBJ treatment reversed this process, indicating that the sphingolipid metabolic pathway is activated in the condition of sepsis-induced ALI as the symbol of cell death.

Arachidonic acid is one of the important polyunsaturated fatty acids (PUFA) and can be biosynthesized from linoleic acid. Arachidonic acid plays a critical role in inflammatory metabolic pathways [31]. The data presented in a pilot study [32] showed that the activity of arachidonic acid metabolites persisted for several days in septic patients. What is more, arachidonic acid proved to activate anti-inflammatory cytokines and inhibit proinflammatory cytokines to prevent pulmonary injury [33].

Lysophosphatidylcholine (LPC) is a critical immunomodulator and has been reported to reduce mortality in septic mice [34]. Previous publication has shown that LPC concentrations on day 7 were significantly lower in nonsurvivors than in survivors and Smani et al. also reported the significant effect of LPC in severe infections [35, 36].

Meanwhile, previous studies illustrated the therapeutic effects of LPC in experimental sepsis, which included the effects on cytokine levels, on enhancing bacterial clearance, on neutrophil deactivation, and on increasing bactericidal activity of neutrophils [34, 37]. In this study, we also observed that most kind of LPC was increased in XBJ treatment group when compared with CLP group.

In summary, the disturbance of purine, glutathione, arachidonic acid, and sphingolipid metabolisms plays critical roles in the progress of sepsis-induced ALI, and XBJ treatment could reverse these metabolic disturbances in varying degrees. These results demonstrate that XBJ injection could relieve sepsis-induced acute lung injury via improving the condition of these 5 metabolic pathways.

However, Xuebijing injection consists of over 20 constituents, and some drug monomers such as ferulic acid and tanshinol can also eliminate oxygen free radicals and regulate lung inflammation [33, 38], so further studies are necessary to elucidate the detailed mechanism underlying the therapeutic efficacy of XBJ.

5. Conclusions

Our study demonstrated a metabonomics approach based on UHPLC/Q-TOF MS to profile the metabolic changes of sepsis-induced acute lung injury in mice and demonstrated that XBJ can alleviate sepsis-induced acute lung injury via purine, glutathione, arachidonic acid, and sphingolipid metabolisms. These pathways may be the potential therapeutic pathways to overcome sepsis-induced acute lung injury and we provided the potential mechanisms of protective effects of XBJ against ALI. However, further studies are needed for better understandings about which compounds of XBJ are involved in this pathophysiological process.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

Xuan Shi, Guannan Chen, and Juan Wei contributed equally to this work.

Acknowledgments

This study was supported in part by grants from the National Natural Science Foundation of China (81272142, 81671947, and 81871601).

References

C. Fleischmann, A. Scherag, N. K. Adhikari et al., “Assessment of global incidence and mortality of hospital-treated sepsis—current estimates and limitations,” American Journal of Respiratory and Critical Care Medicine, vol. 193, no. 3, pp. 259–272, 2015.

J.-L. Vincent, J. C. Marshall, S. A. Ñamendys-Silva et al., “Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit,” The Lancet Respiratory Medicine, vol. 2, no. 5, pp. 380–386, 2014.

E. Abraham and M. Singer, “Mechanisms of sepsis-induced organ dysfunction,” Critical Care Medicine, vol. 35, no. 10, pp. 2408–2416, 2007.

E. P. Schmidt, Y. Yang, W. J. Janssen et al., “The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis,” Nature Medicine, vol. 18, no. 8, pp. 1217–1223, 2012.

B. Andrews, M. W. Semler, L. Muchemwa et al., “Effect of an early resuscitation protocol on in-hospital mortality among adults with sepsis and hypotension: A randomized clinical trial,” Journal of the American Medical Association, vol. 318, no. 13, pp. 1233–1240, 2017.

H. Huang, L. Ji, S. Song et al., “Identification of the major constituents in Xuebijing injection by HPLC-ESI-MS,” Phytochemical Analysis, vol. 22, no. 4, pp. 330–338, 2011.

Y. Hu, Z. Sun, Y. Sun et al., “Rapid determination of 30 bioactive constituents in XueBiJing injection using ultra high performance liquid chromatography-high resolution hybrid quadrupole-orbitrap mass spectrometry coupled with principal component analysis,” Journal of Pharmaceutical and Biomedical Analysis, vol. 137, pp. 220–228, 2017.

Q. Yin and C. Li, “Treatment effects of Xuebijing Injection in severe septic patients with disseminated intravascular coagulation,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 949254, 6 pages, 2014.

H. Shi, Y. Hong, J. Qian, X. Cai, and S. Chen, “Xuebijing in the treatment of patients with sepsis,” The American Journal of Emergency Medicine, vol. 35, no. 2, pp. 285–291, 2017.

J. K. Nicholson and J. C. Lindon, “Systems biology: metabonomics,” Nature, vol. 455, no. 7216, pp. 1054–1056, 2008.

X. Liu and J. W. Locasale, “Metabolomics: a primer,” Trends in Biochemical Sciences, vol. 42, no. 4, pp. 274–284, 2017.

P. Lacy, “Metabolomics of sepsis-induced acute lung injury: a new approach for biomarkers,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 300, no. 1, pp. L1–L3, 2011.

K. A. Stringer, N. J. Serkova, A. Karnovsky, K. Guire, R. Paine, and T. J. Standiford, “Metabolic consequences of sepsis-induced acute lung injury revealed by plasma,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 300, no. 1, pp. L4–L11, 2011.

Y. Imai, K. Kuba, S. Rao et al., “Angiotensin-converting enzyme 2 protects from severe acute lung failure,” Nature, vol. 436, no. 7047, pp. 112–116, 2005.

Q. Wang, X. Wu, X. Tong, Z. Zhang, B. Xu, and W. Zhou, “Xuebijing Ameliorates sepsis-induced lung injury by downregulating HMGB1 and RAGE expressions in mice,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 860259, 9 pages, 2015.

R. Tautenhahn, G. J. Patti, D. Rinehart, and G. Siuzdak, “XCMS Online: a web-based platform to process untargeted metabolomic data,” Analytical Chemistry, vol. 84, no. 11, pp. 5035–5039, 2012.

A. K. Smilde, M. J. Van Der Werf, S. Bijlsma, B. J. C. Van Der Werff-Van Der Vat, and R. H. Jellema, “Fusion of mass spectrometry-based metabolomics data,” Analytical Chemistry, vol. 77, no. 20, pp. 6729–6736, 2005.

J. Trygg, E. Holmes, and T. Lundstedt, “Chemometrics in metabonomics,” Journal of Proteome Research, vol. 6, no. 2, pp. 469–479, 2007.

D. S. Wishart, T. Jewison, A. C. Guo et al., “HMDB 3.0—the human metabolome database in 2013,” Nucleic Acids Research, vol. 41, no. 1, pp. D801–D807, 2013.

G. Tan, Z. Lou, W. Liao et al., “Hydrophilic interaction and reversed-phase ultraperformance liquid chromatographyTOF-MS for serum metabonomic analysis of myocardial infarction in rats and its applications,” Mol. BioSyst., vol. 8, no. 2, pp. 548–556, 2012.

M. A. Matthay, G. A. Zimmerman, C. Esmon et al., “Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute Working Group,” American Journal of Respiratory and Critical Care Medicine, vol. 167, no. 7, pp. 1027–1035, 2003.

K. Ji, L. Xue, J. Cheng, and Y. Bai, “Preconditioning of H2S inhalation protects against cerebral ischemia/reperfusion injury by induction of HSP70 through PI3K/Akt/Nrf2 pathway,” Brain Research Bulletin, vol. 121, pp. 68–74, 2016.

M. Moritz, S. Pfeifer, E. R. Balmayor et al., “VEGF released from a fibrin biomatrix increases VEGFR-2 expression and improves early outcome after ischaemia–reperfusion injury,” Journal of Tissue Engineering and Regenerative Medicine, vol. 11, no. 7, pp. 2153–2163, 2017.

H. Wang, L.-J. Hong, J.-Y. Huang et al., “P2RX 7 sensitizes Mac-1/ICAM-1-dependent leukocyte-endothelial adhesion and promotes neurovascular injury during septic encephalopathy,” Cell Research, vol. 25, no. 6, pp. 674–690, 2015.

S. R. Akbar, D. M. Long, K. Hussain et al., “Hyperuricemia: an early marker for severity of illness in sepsis,” International Journal of Nephrology, vol. 2015, Article ID 301021, 8 pages, 2015.

D. Brealey, M. Brand, I. Hargreaves et al., “Association between mitochondrial dysfunction and severity and outcome of septic shock,” The Lancet, vol. 360, no. 9328, pp. 219–223, 2002.

W. Hoetzenecker, B. Echtenacher, E. Guenova et al., “ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression,” Nature Medicine, vol. 18, no. 1, pp. 128–134, 2012.

O. Ortolani, A. Conti, A. R. De Gaudio, E. Moraldi, Q. Cantini, and G. Novelli, “The effect of glutathione and N-acetylcysteine on lipoperoxidative damage in patients with early septic shock,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 6, pp. 1907–1911, 2000.

Y. Zong and H. Zhang, “Amentoflavone prevents sepsis-associated acute lung injury through Nrf2-GCLc-mediated upregulation of glutathione,” Acta Biochimica Polonica, vol. 64, no. 1, pp. 93–98, 2017.

M. J. Hernández-Corbacho, M. F. Salama, D. Canals, C. E. Senkal, and L. M. Obeid, “Sphingolipids in mitochondria,” Biochimica et Biophysica Acta, vol. 1862, no. 1, pp. 56–68, 2017.

S. Kim, L. Dayani, P. A. Rosenberg, and J. Li, “RIP1 kinase mediates arachidonic acid-induced oxidative death of oligodendrocyte precursors,” International Journal of Physiology, Pathophysiology and Pharmacology, vol. 2, no. 2, pp. 137–147, 2010.

G. R. Bernard, A. P. Wheeler, J. A. Russell et al., “The effects of ibuprofen on the physiology and survival of patients with sepsis,” The New England Journal of Medicine, vol. 336, no. 13, pp. 912–918, 1997.

M. Liu, M. Su, W. Zhang et al., “Protective effect of Xuebijing injection on paraquat-induced pulmonary injury via down-regulating the expression of p38 MAPK in rats,” BMC Complementary and Alternative Medicine, vol. 14, article 498, 2014.

J.-J. Yan, J.-S. Jung, J.-E. Lee et al., “Therapeutic effects of lysophosphatidylcholine in experimental sepsis,” Nature Medicine, vol. 10, no. 2, pp. 161–167, 2004.

D. W. Park, D. S. Kwak, Y. Y. Park et al., “Impact of serial measurements of lysophosphatidylcholine on 28-day mortality prediction in patients admitted to the intensive care unit with severe sepsis or septic shock,” Journal of Critical Care, vol. 29, no. 5, pp. 882–882.e11, 2014.

Y. Smani, J. Domínguez-Herrera, J. Ibáñez-Martínez, and J. Pachóna, “Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii,” Antimicrobial Agents and Chemotherapy, vol. 59, no. 7, pp. 3920–3924, 2015.

G. Chen, J. Li, X. Qiang et al., “Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: An additional mechanism for its therapeutic effects in experimental sepsis,” Journal of Lipid Research, vol. 46, no. 4, pp. 623–627, 2005.

Y. Chen, H. Tong, Z. Pan et al., “Xuebijing injection attenuates pulmonary injury by reducing oxidative stress and proinflammatory damage in rats with heat stroke,” Experimental and Therapeutic Medicine, vol. 13, no. 6, pp. 3408–3416, 2017.